Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,270Revenue $M3.6Net Margin (%)-3,292.8Z-Score-1.2
Enterprise Value $M2,071EPS $-1.3Operating Margin %-3,414.1F-Score4
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-3,292.8Higher ROA y-yY
Price/Book10.710-y EBITDA Growth Rate %0Quick Ratio8.4Cash flow > EarningsY
Price/Sales6335-y EBITDA Growth Rate %0Current Ratio8.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-39.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-44.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M89.6ROI % (ttm)-48.8Gross Margin Increase y-yY

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJean-Marie Eveillard 2014-12-31 Add0.01%$12.55 - $20.93
($16.61)
$ 25.3334%Add 123.82%559,542
CLDXJean-Marie Eveillard 2014-09-30 Buy 0.01%$12.05 - $17.57
($14.51)
$ 25.3343%New holding250,000
CLDXJean-Marie Eveillard 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 25.33-1%Sold Out0
CLDXJean-Marie Eveillard 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 25.33-1%Reduce -75.45%135,000
CLDXJean-Marie Eveillard 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 25.3348%Reduce -45.89%665,560
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 25.3383%Sold Out0
CLDXJean-Marie Eveillard 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 25.3383%Add 260.87%1,660,000
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 25.3384%New holding803,200
CLDXJean-Marie Eveillard 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 25.3384%Add 360.00%460,000
CLDXJean-Marie Eveillard 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 25.3389%Reduce -71.43%100,000
CLDXJean-Marie Eveillard 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 25.3385%New holding350,000
CLDXJean-Marie Eveillard 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 25.3381%Sold Out0
CLDXJean-Marie Eveillard 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 25.3381%New holding100,000
CLDXJean-Marie Eveillard 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 25.3375%Sold Out0
CLDXJean-Marie Eveillard 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 25.3366%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
van den Broek RichardDirector 2014-12-17Sell0$0view
CATLIN AVERY WSr. VP & CFO 2013-12-06Sell183,333$24.522.33view
ELLBERGER LARRYDirector 2013-12-06Sell17,728$24.522.33view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.522.33view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.522.33view
KELER TIBORSr. VP & CSO 2011-08-11Buy5,000$2.51098.8view
Marucci Anthony SPresident & CEO 2011-08-09Buy15,000$2.411143.57view
CATLIN AVERY WSr. VP & CFO 2011-08-09Buy2,000$2.391153.97view
Davis Thomas AndrewSr. VP & CMO 2010-09-16Buy2,500$3.77694.96view
LIPTON KAREN SHOOSDirector 2010-09-16Buy3,000$3.74701.34view

Press Releases about CLDX :

    Quarterly/Annual Reports about CLDX:

    News about CLDX:

    Articles On GuruFocus.com
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
    Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
    CLDX up 223%, Cohen Gains Big Apr 23 2013 
    Steve Cohen Increases Celldex Up 145% Apr 06 2013 
    comment on CLDX Mar 06 2013 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
    Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 

    More From Our Partners
    Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015 - ZACKS

    More From Other Websites
    Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in... Apr 20 2015
    Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in... Apr 20 2015
    Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015
    Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog Apr 07 2015
    Celldex Up As Breast-Cancer Drug Shows Promise Apr 07 2015
    Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched Apr 07 2015
    Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer... Apr 06 2015
    Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer... Apr 06 2015
    Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with... Apr 06 2015
    Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with... Apr 06 2015
    Celldex, Roche Ink Deal to Develop Kidney Cancer Drug - Analyst Blog Mar 18 2015
    Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination... Mar 17 2015
    Celldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination... Mar 17 2015
    Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog Mar 05 2015
    CELLDEX THERAPEUTICS, INC. Financials Mar 03 2015
    Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health... Mar 03 2015
    Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health... Mar 03 2015
    Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares Feb 28 2015
    Celldex Announces Exercise of Underwriters' Option to Purchase Additional Shares Feb 27 2015
    Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences Feb 27 2015
    10-K for Celldex Therapeutics, Inc. Feb 26 2015
    CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 26 2015
    Celldex Therapeutics Prices Public Offering of Common Stock Feb 25 2015
    Celldex Therapeutics Announces Proposed Public Offering of Common Stock Feb 25 2015
    Celldex Therapeutics Prices Public Offering of Common Stock Feb 25 2015
    Celldex Therapeutics (CLDX) Stock Rises Today on Rintega FDA Designation, Fourth-Quarter Earnings Feb 24 2015
    Celldex reports 4Q loss Feb 24 2015
    Celldex reports 4Q loss Feb 24 2015
    Celldex Therapeutics (CLDX) Wider-than-Expected Loss in Q4 - Tale of the Tape Feb 24 2015
    CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 24 2015
    Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment... Feb 24 2015
    Celldex Reports Fourth Quarter and Year-End 2014 Results Feb 24 2015
    Q4 2014 Celldex Therapeutics Inc Earnings Release - Before Market Open Feb 24 2015
    Celldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare... Feb 09 2015
    Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of... Jan 29 2015
    Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of... Jan 29 2015
    Celldex Therapeutics Announces Appointment to Board of Directors Dec 18 2014
    Celldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced... Dec 04 2014
    Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial... Nov 10 2014
    Celldex Presents Varlilumab Proof of Concept Data at SITC Annual Meeting 2014 Nov 07 2014
    Celldex tops Street 3Q forecasts Nov 05 2014
    Celldex Reports Third Quarter 2014 Results Nov 04 2014
    Celldex Therapeutics Announces Upcoming Presentations of Rindopepimut Data at 19th Annual Scientific... Nov 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK